Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

被引:21
|
作者
Sun, Mengmeng [1 ]
Zeng, Han [1 ]
Jin, Kaifeng [1 ]
Liu, Zhaopei [1 ]
Hu, Baoying [2 ]
Liu, Chunnan [1 ]
Yan, Sen [1 ]
Yu, Yanze [1 ]
You, Runze [1 ]
Zhang, Hongyi [1 ]
Chang, Yuan [3 ]
Liu, Li [4 ]
Zhu, Yu [3 ]
Xu, Jiejie [1 ]
Xu, Le [5 ]
Wang, Zewei [4 ]
机构
[1] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai 200032, Peoples R China
[2] Nantong Univ, Sch Med, Dept Immunol, Nantong, Peoples R China
[3] Fudan Univ Shanghai, Dept Urol, Canc Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Urol, Sch Med, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
Tumor-associated macrophages; Muscle-invasive bladder cancer; Adjuvant chemotherapy; Immunotherapy; Tumor-immune microenvironment; BLOCKADE;
D O I
10.1007/s00262-021-03098-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Muscle-invasive bladder cancer (MIBC) is an aggressive and heterogeneous malignancy. Tumor-associated macrophages (TAMs) are key infiltrating cell populations in the inflammatory microenvironment of malignant tumors including MIBC. It intrigues us to explore the clinical significance and immunoregulatory role of TAMs infiltration and polarization in MIBC. Methods A total of 141 patients with MIBC from Zhongshan Hospital and 391 patients with MIBC from The Cancer Genome Atlas (TCGA) database were included in this study. Moreover, 195 patients who received anti-PD-L1 therapy from the IMvigor210 trial were enrolled. Patients were categorized into three subtypes considering the infiltration level and polarization status of TAMs, denoted as TAM(low) (Subtype I), TAM(high)&M2/M1(low) (Subtype II), and TAM(high)&M2/M1(high) (Subtype III). Results Subtype III suffered inferior prognosis, and Subtype II could benefit more from adjuvant chemotherapy (ACT). Subtype III was featured with increased pro-tumor cells and immunosuppressive cytokines, while Subtype II possessed more immunogenic cells infiltration with activated and tumoricidal properties. Subtype II and Subtype III presented basal/squamous-like characterization and showed additional prognostic merit beyond molecular classification. Subtype I exhibited elevated level of FGFR3 signature, while Subtype II had EGFR signaling activation and immunotherapeutic indication. Additionally, Subtype II patients were indeed highly sensitive to PD-L1 blockade therapy in IMvigor210 trial. Conclusion The infiltration and polarization status of TAMs shaped distinct immune microenvironment with predictive significance for survival outcome, ACT benefit, and PD-L1 blockade therapy sensitivity in MIBC. Immune classification based on TAMs polarization and infiltration might provide tools to tailor chemotherapy and immunotherapy.
引用
收藏
页码:1497 / 1506
页数:10
相关论文
共 50 条
  • [41] Systemic Immune Inflammation Index and T-Staging Predict Prognosis in Patients with Muscle-Invasive Bladder Cancer
    Zhang, Xiaoping
    Liu, Quan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2023, 76 (07): : 511 - 518
  • [42] Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?
    Niegisch, Guenter
    Lorch, Anja
    Droller, Michael J.
    Lavery, Hugh J.
    Stensland, Kristian D.
    Albers, Peter
    EUROPEAN UROLOGY, 2013, 64 (03) : 355 - 357
  • [43] Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers
    Kool, Ronald
    Mansure, Jose Joao
    Kassouf, Wassim
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S325 - S328
  • [44] Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer
    Yu, Yanze
    Zeng, Han
    Jin, Kaifeng
    You, Runze
    Liu, Zhaopei
    Zhang, Hongyi
    Liu, Chunnan
    Su, Xiaohe
    Yan, Sen
    Chang, Yuan
    Liu, Li
    Xu, Le
    Xu, Jiejie
    Zhu, Yu
    Wang, Zewei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (09) : 2117 - 2126
  • [45] Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer
    Yanze Yu
    Han Zeng
    Kaifeng Jin
    Runze You
    Zhaopei Liu
    Hongyi Zhang
    Chunnan Liu
    Xiaohe Su
    Sen Yan
    Yuan Chang
    Li Liu
    Le Xu
    Jiejie Xu
    Yu Zhu
    Zewei Wang
    Cancer Immunology, Immunotherapy, 2022, 71 : 2117 - 2126
  • [46] Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy
    Leblond, Marine M.
    Zdimerova, Hana
    Desponds, Emma
    Verdeil, Gregory
    CANCERS, 2021, 13 (18)
  • [47] Prognostic Value of Tumor-associated Macrophages Count in Human Non-muscle-invasive Bladder Cancer Treated by BCG Immunotherapy
    Ajili, Faouzia
    Kourda, Nadia
    Darouiche, Amine
    Chebil, Mouhamed
    Boubaker, Samir
    ULTRASTRUCTURAL PATHOLOGY, 2013, 37 (01) : 56 - 61
  • [48] A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications
    Sedighzadeh, Sahar Sadat
    Khoshbin, Amin Pastaki
    Razi, Sepideh
    Keshavarz-Fathi, Mahsa
    Rezaei, Nima
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (04) : 1889 - 1916
  • [49] A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer
    Wang, Weizhuo
    Zhang, Xi
    Jiang, Silin
    Xu, Peng
    Chen, Kang
    Li, Kai
    Wang, Fei
    Le, Xiang
    Zhang, Ke
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis
    Ye, Ruiting
    Zeng, Han
    Liu, Zhaopei
    Jin, Kaifeng
    Liu, Chunnan
    Yan, Sen
    Yu, Yanze
    You, Runze
    Zhang, Hongyi
    Chang, Yuan
    Wang, Yiwei
    Liu, Li
    Zhu, Yu
    Xu, Jiejie
    Xu, Le
    Wang, Zewei
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (02) : 301 - 310